Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 305Carcinoma, Non-Small-Cell Lung 287Colorectal Neoplasms 159Prostatic Neoplasms 158Carcinoma, Hepatocellular 144Neoplasms 137Leukemia, Myeloid, Acute 131Lung Neoplasms 117Squamous Cell Carcinoma of Head and Neck 108Multiple Myeloma 104Triple Negative Breast Neoplasms 102Recurrence 101Pancreatic Neoplasms 96Stomach Neoplasms 94Ovarian Neoplasms 89Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Esophageal Neoplasms 68Uterine Cervical Neoplasms 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Melanoma 67Brain Neoplasms 67Rectal Neoplasms 64Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 58Myelodysplastic Syndromes 55Lymphoma 55Esophageal Squamous Cell Carcinoma 54

Interventions

enzalutamide 1apalutamide 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Neoadjuvant Therapy × Clear all
NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
900 enrolled
Genitourinary

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡